Timothy S Weeden

US Patent:

20090297444, Dec 3, 2009

Filed:

Mar 20, 2009

Appl. No.:

12/408560

Inventors:

Michael A. Perricone - Sudbury MA, US
John Lyle Dzuris - Roslindale MA, US
Timothy E. Weeden - Sturbridge MA, US
James E. Stefano - Hopkinton MA, US
Clark Q. Pan - Sudbury MA, US
Andrea E. Edling - Milford MA, US

International Classification:

A61K 51/08
C07K 7/08
A61K 38/10
A61P 29/00

US Classification:

424 169, 530327, 514 14

Abstract:

Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (α-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the α-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.

US Patent:

20130303452, Nov 14, 2013

Filed:

May 8, 2013

Appl. No.:

13/890039

Inventors:

John Lyle DZURIS - Roslindale MA, US
Timothy E. WEEDEN - Sturbridge MA, US
James E. STEFANO - Hopkinton MA, US
Clark Q. PAN - Sudbury MA, US
Andrea E. EDLING - Milford MA, US

International Classification:

C07K 7/08

US Classification:

514 107

Abstract:

Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (α-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the α-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.

US Patent:

20220378934, Dec 1, 2022

Filed:

Aug 2, 2019

Appl. No.:

17/265044

Inventors:

- Waltham MA, US
Mohammed T. Qatanani - Waltham MA, US
Timothy Weeden - Waltham MA, US

Assignee:

Dyne Therapeutics, Inc. - Waltham MA

International Classification:

A61K 47/68
C07K 16/28

Abstract:

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits activity of a pro-atrophy gene. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

US Patent:

20220324992, Oct 13, 2022

Filed:

Jun 22, 2022

Appl. No.:

17/846738

Inventors:

- Waltham MA, US
Mohammed T. Qatanani - Waltham MA, US
Timothy Weeden - Waltham MA, US

Assignee:

Dyne Therapeutics, Inc. - Waltham MA

International Classification:

C07K 16/28
C12N 15/113

Abstract:

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

US Patent:

20220288220, Sep 15, 2022

Filed:

May 24, 2022

Appl. No.:

17/751875

Inventors:

- Waltham MA, US
Mohammed T. Qatanani - Waltham MA, US
Timothy Weeden - Waltham MA, US

Assignee:

Dyne Therapeutics, Inc. - Waltham MA

International Classification:

A61K 47/68
A61P 21/00
C07K 16/28
C12N 15/113
A61K 47/54
A61K 47/10

Abstract:

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

US Patent:

20220193250, Jun 23, 2022

Filed:

Aug 2, 2019

Appl. No.:

17/264948

Inventors:

- Waltham MA, US
Mohammed T. Qatanani - Waltham MA, US
Timothy Weeden - Waltham MA, US

Assignee:

Dyne Therapeutics, Inc. - Waltham MA

International Classification:

A61K 47/68
A61P 21/00

Abstract:

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

US Patent:

20230111147, Apr 13, 2023

Filed:

Jan 8, 2021

Appl. No.:

17/791670

Inventors:

- Waltham MA, US
Mohammed T. Qatanani - Waltham MA, US
Cody A. Desjardins - Waltham MA, US
Duncan Brown - Berkeley CA, US
Victor Kotelianski - Newton MA, US
Timothy Weeden - Waltham MA, US
Brendan Quinn - Boston MA, US

Assignee:

Dyne Therapeutics, Inc. - Waltham MA

International Classification:

C07K 16/28

Abstract:

Aspects of the disclosure relate to molecular payloads that modulate the expression or activity of genes involved in muscle growth and maintenance (e.g., MSTN, INHBA, and/or ACVR1B), and complexes comprising a muscle-targeting agent covalently linked to such molecular payloads. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on a muscle cell (e.g., a cardiac muscle cell). In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

US Patent:

20230111212, Apr 13, 2023

Filed:

Jan 8, 2021

Appl. No.:

17/791701

Inventors:

- Waltham MA, US
Mohammed T. Qatanani - Waltham MA, US
Timothy Weeden - Waltham MA, US
Cody A. Desjardins - Waltham MA, US
Brendan Quinn - Boston MA, US
Jason P. Rhodes - Waltham MA, US

Assignee:

Dyne Therapeutics, Inc. - Waltham MA

International Classification:

A61K 47/68
A61P 21/00

Abstract:

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.